Combination of rituximab with chemotherapy in diffuse large B-cell lymphoma. Evaluation in daily practice before and after approval of rituximab in this indication

Hematological Oncology

Volumn 26, Issue 3, 2008, Pages 139-147

  Ghesquières, Hervé ^a   Ferlay, Céline ^a   Sebban, Catherine ^a   Chassagne, Catherine ^a   Carasu, Liana ^a   Gargi, Thérèse ^a   Favier, Bertrand ^a   Philip, Irène ^a   Blay, Jean Yves ^a   Biron, Pierre ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Chemotherapy; Daily practice; Diffuse large B cell lymphoma; Rituximab

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; PREDNISONE; RITUXIMAB; VINBLASTINE; VINCRISTINE; VINDESINE; MONOCLONAL ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LARGE CELL LYMPHOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES;

EID: 55249123369     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.850     Document Type: Article

References (23)

1. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 2780-2795.
2. Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005; 23: 6387-6393.
3. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
4. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-3127.
5. Pfreundschuh M, Kloess M, Zeynalova S, et al. Six vs. eight cycles of bi-weekly CHOP-14 with or without rituximab for elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the completed RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL). Blood 2006; 108: The American Society of Hematology 48th Annual Meeting and Exposition; December 9-12, 2006; Orlando, FL. Abstract 205.
6. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-391.
7. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
8. Coiffier B. Fourteen years of high-dose CHOP (ACVB regimen): preliminary conclusions about the treatment of aggressive-lymphoma patients. Hamilton Fairley Award Lecture, European Society for Medical Oncology Meeting, Lisbon, November 21, 1994. Ann Oncol 1995; 6: 211-217.
9. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
10. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1-39.
11. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-346.
12. Cox D. Regression model and lifer tables (with discussion). J R Stat Soc 1972; 34: 187-220.
13. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-5033.
14. Park YH, Lee JJ, Ryu MH, et al. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Ann Hematol 2006; 85: 257-262.
15. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH 97-2protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025-3030.
16. Merli F, Bertini M, Luminari S, et al. Long term results of a randomized study performed by Intergruppo Italiano Linfomi comparing Mini-CEOP vs P-VEBEC in elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma 2007; 48: 367-373.
17. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-4126.
18. Glass B, Kloess M, Engert A, et al. Dose escalated CHOP + etoposide and repetitive autologous stem cell transplantation (MegaCHOEP) with and without rituximab for primary treatment of aggressive NHL. ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23: abstract 6654.
19. Belhadj K, Fitoussi O, Haioun C, et al. Rituximab combined to ACVBP (R-ACVBP) as a new inductive treatment followed by high-dose consolidative autotransplantation (HDC) for poor risk diffuse large B-cell lymphoma (DLBCL) in first-line. Preliminary results on 119 patients of a GELA phase II study. Blood 2006; 108: The American Society of Hematology 48th Annual Meeting and Exposition; December 9-12, 2006; Orlando, FL. Abstract 3049.
20. Tarella C, Zanni M, Magni M, et al. Benefit of rituximab addition to high-dose programs with autograft for B-cell lymphoma: a multicenter GITIL survey on 957 patients. Blood 2006; 108: The American Society of Hematology 48th Annual Meeting and Exposition; December 9-12, 2006; Orlando, FL. Abstract 207.
21. Mounier N, Briere J, Gisselbrecht C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2 - associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279-4284.
22. Winter JN, Weller EA, Horning SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006; 107: 4207-4213.
23. Andre F, Slimane K, Bachelot T, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol 2004; 22: 3302-3308.